SNGX Headlines 2 Small-Cap Health Care Stocks Cr
Post# of 102251
Posted On: 10/26/2013 5:22:12 PM
SNGX Headlines
2 Small-Cap Health Care Stocks Creating Investor Buzz 1:52 p.m. Oct. 7, 2013 - Wall St. Cheat Sheet
FDA Grants Soligenix Orphan Drug Designation for SGX94 6:03 a.m. Sept. 16, 2013 - benzinga.com
4 Promising Biotech Stocks With Upcoming Catalysts 12:37 p.m. Aug. 25, 2013 - Wall St. Cheat Sheet
10-Q: SOLIGENIX, INC. 9:22 a.m. Aug. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Intrexon IPO Filing: Better DNA for Healthcare, Food, Energy, Environment 6:05 p.m. July 9, 2013 - 247WallSt.com
Soligenix Completes Phase 1 Pediatric Crohn's Disease Clinical Study 6:17 a.m. June 28, 2013 - benzinga.com
10-Q: SOLIGENIX, INC. 7:29 a.m. May 3, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: SOLIGENIX, INC. 3:29 p.m. Feb. 26, 2013 - Edgar Online - (EDG = 10Q, 10K)
Soligenix Receives FDA Orphan Drug Designation for OrbeShield for Treatment after Exposure to Radiological Disaster 7:25 a.m. Jan. 2, 2013 - benzinga.com
Soligenix Regains North American, European Rights to Oral BDP 7:20 a.m. Dec. 27, 2012 - benzinga.com
10-Q: SOLIGENIX, INC. 9:04 a.m. Nov. 14, 2012 - Edgar Online - (EDG = 10Q, 10K)
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors 7:15 a.m. Oct. 21, 2013 - PR Newswire
Soligenix Announces Formation of International Melioidosis Scientific Advisory Board 7:15 a.m. Oct. 17, 2013 - PR Newswire
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development 7:30 a.m. Oct. 3, 2013 - PR Newswire
Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield(TM) in GI ARS 7:00 a.m. Sept. 25, 2013 - PR Newswire
Soligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield(TM) in GI ARS 7:15 a.m. Sept. 19, 2013 - PR Newswire
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome 7:00 a.m. Sept. 16, 2013 - PR Newswire
Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City 7:00 a.m. Sept. 5, 2013 - PR Newswire
Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments 7:15 a.m. Aug. 12, 2013 - PR Newswire
Soligenix Announces Commercial Collaboration with SciClone Pharmaceuticals in China for SGX942 in the Treatment of Oral Mucositis 7:30 a.m. July 8, 2013 - PR Newswire
Soligenix Completes Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease 7:15 a.m. June 28, 2013 - PR Newswire
Soligenix Closes $7.1 Million Public Offering 7:15 a.m. June 26, 2013 - PR Newswire
Soligenix Announces Pricing of Public Offering of Common Stock and Warrants 7:00 a.m. June 21, 2013 - PR Newswire
FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer 7:30 a.m. June 3, 2013 - PR Newswire
Soligenix Announces Issuance of US Patent for its ThermoVax(TM) Technology 7:00 a.m. May 22, 2013 - PR Newswire
Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease 7:00 a.m. May 15, 2013 - PR Newswire
Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments 7:00 a.m. May 3, 2013 - PR Newswire
Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration 7:30 a.m. May 1, 2013 - PR Newswire
Soligenix to Present at World Vaccine Congress & Expo 7:00 a.m. April 16, 2013 - PR Newswire
Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis 7:00 a.m. March 27, 2013 - PR Newswire
Soligenix Announces Significant Progress with ThermoVax(TM) Towards the Development of Heat Stable Vaccines 7:00 a.m. March 19, 2013 - PR Newswire
2 Small-Cap Health Care Stocks Creating Investor Buzz 1:52 p.m. Oct. 7, 2013 - Wall St. Cheat Sheet
FDA Grants Soligenix Orphan Drug Designation for SGX94 6:03 a.m. Sept. 16, 2013 - benzinga.com
4 Promising Biotech Stocks With Upcoming Catalysts 12:37 p.m. Aug. 25, 2013 - Wall St. Cheat Sheet
10-Q: SOLIGENIX, INC. 9:22 a.m. Aug. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Intrexon IPO Filing: Better DNA for Healthcare, Food, Energy, Environment 6:05 p.m. July 9, 2013 - 247WallSt.com
Soligenix Completes Phase 1 Pediatric Crohn's Disease Clinical Study 6:17 a.m. June 28, 2013 - benzinga.com
10-Q: SOLIGENIX, INC. 7:29 a.m. May 3, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: SOLIGENIX, INC. 3:29 p.m. Feb. 26, 2013 - Edgar Online - (EDG = 10Q, 10K)
Soligenix Receives FDA Orphan Drug Designation for OrbeShield for Treatment after Exposure to Radiological Disaster 7:25 a.m. Jan. 2, 2013 - benzinga.com
Soligenix Regains North American, European Rights to Oral BDP 7:20 a.m. Dec. 27, 2012 - benzinga.com
10-Q: SOLIGENIX, INC. 9:04 a.m. Nov. 14, 2012 - Edgar Online - (EDG = 10Q, 10K)
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors 7:15 a.m. Oct. 21, 2013 - PR Newswire
Soligenix Announces Formation of International Melioidosis Scientific Advisory Board 7:15 a.m. Oct. 17, 2013 - PR Newswire
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development 7:30 a.m. Oct. 3, 2013 - PR Newswire
Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield(TM) in GI ARS 7:00 a.m. Sept. 25, 2013 - PR Newswire
Soligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield(TM) in GI ARS 7:15 a.m. Sept. 19, 2013 - PR Newswire
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome 7:00 a.m. Sept. 16, 2013 - PR Newswire
Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City 7:00 a.m. Sept. 5, 2013 - PR Newswire
Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments 7:15 a.m. Aug. 12, 2013 - PR Newswire
Soligenix Announces Commercial Collaboration with SciClone Pharmaceuticals in China for SGX942 in the Treatment of Oral Mucositis 7:30 a.m. July 8, 2013 - PR Newswire
Soligenix Completes Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease 7:15 a.m. June 28, 2013 - PR Newswire
Soligenix Closes $7.1 Million Public Offering 7:15 a.m. June 26, 2013 - PR Newswire
Soligenix Announces Pricing of Public Offering of Common Stock and Warrants 7:00 a.m. June 21, 2013 - PR Newswire
FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer 7:30 a.m. June 3, 2013 - PR Newswire
Soligenix Announces Issuance of US Patent for its ThermoVax(TM) Technology 7:00 a.m. May 22, 2013 - PR Newswire
Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease 7:00 a.m. May 15, 2013 - PR Newswire
Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments 7:00 a.m. May 3, 2013 - PR Newswire
Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration 7:30 a.m. May 1, 2013 - PR Newswire
Soligenix to Present at World Vaccine Congress & Expo 7:00 a.m. April 16, 2013 - PR Newswire
Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis 7:00 a.m. March 27, 2013 - PR Newswire
Soligenix Announces Significant Progress with ThermoVax(TM) Towards the Development of Heat Stable Vaccines 7:00 a.m. March 19, 2013 - PR Newswire
(0)
(0)Scroll down for more posts ▼